Table 1:
Characteristics of included people in N3C cohort, December 10, 2020 - June 07, 2022
| Cohort 1 | Cohort 1∣ Cohort 2 | Cohort 1∣ Cohort 2 | Cohort 2 | |
|---|---|---|---|---|
| Non-vaccinated pregnant people (n=231,662) | Pregnant people with initial vaccination during pregnancy (n=34,907) | Pregnant people with initial vaccination before pregnancy (n=34,538) | Non-pregnant vaccinated females aged 15 - 55 years old (n= 864,892) | |
| Age (mean (IQR)) | 30.2 (25, 33.8) | 31.9 (28.0, 36.1) | 32.2 (28.2, 35.9) | 37.1 (28.1, 47.2) |
| BMI | ||||
| BMI in kg/m2, median (IQR) | 27.5 (23.3, 33.5) | 27.4 (23.3, 33.2) | 27.5 (23.4, 33.2) | 29.4 (24.3, 36.0) |
| Missing | 166,165 (69.92%) | 22,776 (65.25%) | 18,986 (54.97%) | 551,220 (63.7%) |
| Race/ethnicity | ||||
| White/non-Latinx | 118,663 (51.22%) | 18,731 (53.66%) | 20,545 (59.49%) | 514,957 (59.54%) |
| Black/non-Latinx | 42,393 (18.30%) | 4,574 (13.10%) | 3,877 (11.23%) | 120,639 (13.95%) |
| Any race/Latinx | 38,382 (16.57%) | 7,009 (20.08%) | 5,699 (16.50%) | 125,068 (14.46%) |
| Asian American | 7,880 (3.40%) | 1,850 (5.30%) | 1,770 (5.12%) | 30,391 (3.51%) |
| Other | 3,376 (1.46%) | 676 (1.94%) | 578 (1.67%) | 20,016 (2.31%) |
| Missing | 20,968 (9.05%) | 2,067 (5.92%) | 2,069 (5.99%) | 53,821 (6.22%) |
| Region | ||||
| Midwest | 32,413 (13.99%) | 2,914 (8.35%) | 2,736 (7.92%) | 63,146 (7.30%) |
| South | 34,333 (14.82%) | 8,284 (23.73%) | 8,071 (23.37%) | 159,907 (18.49%) |
| West | 24,321 (10.50%) | 3,951 (11.32%) | 5,389 (15.60%) | 102,324 (11.83%) |
| Northeast | 21,006 (9.07%) | 2,620 (7.51%) | 2,125 (6.15%) | 52,118 (6.03%) |
| Missing | 119,589 (51.62%) | 17,138 (49.10%) | 16,217 (46.95%) | 487,397 (56.35%) |
| Comorbidities | ||||
| Asthma | 30,038 (12.97%) | 4,719 (13.52%) | 4,781 (13.84%) | 112,973 (13.06%) |
| COPD | 933 (0.40%) | 144 (0.41%) | 187 (0.54%) | 12,467 (1.44%) |
| Chronic kidney disease | 1,962 (0.85%) | 353 (1.01%) | 368 (1.07%) | 17,242 (1.99%) |
| Hypertension | 2,789 (1.20%) | 424 (1.21%) | 431 (1.25%) | 10,338 (1.20%) |
| Cardiovascular disease | 24,475 (10.56%) | 3,362 (9.63%) | 3,201 (9.27%) | 89,477 (10.35%) |
| Type I diabetes | 2,632 (1.14%) | 427 (1.22%) | 394 (1.14%) | 8,743 (1.01%) |
| Type II diabetes | 9,780 (4.22%) | 1,749 (5.01%) | 1,698 (4.92%) | 73,814 (8.53%) |
| CCI Index | ||||
| CCI=0 | 43,452 (18.76%) | 6,785 (19.44%) | 6,895 (19.96%) | 165,799 (19.17%) |
| CCI=1 | 9,371 (4.05%) | 1,600 (4.58%) | 1,820 (5.27%) | 63,926 (7.39%) |
| CCI=2 | 169,671 (73.24%) | 25,068 (71.81%) | 24,391 (70.62%) | 571,002 (66.02%) |
| CCI=3+ | 9,168 (3.96%) | 1,454 (4.17%) | 1,432 (4.15%) | 64,165 (7.42%) |
| First vaccine manufacturer | ||||
| Pfizer/BioNTech | 25,540 (73.17%) | 23,547 (68.18%) | 576,921 (66.70%) | |
| Moderna | 8,026 (22.99%) | 9,130 (26.43%) | 239,928 (27.74%) | |
| Janssen | 1,195 (3.42%) | 1,773 (5.13%) | 46,919 (5.42%) | |
| Other | 146 (0.42%) | 88 (0.25%) | 1,124 (0.13%) | |
| Insurance type | ||||
| Private insurance | 32,791 (14.15%) | 6,726 (19.27%) | 7,819 (22.64%) | 160,659 (18.58%) |
| Medicare/Medicaid | 27,857 (12.02%) | 3,843 (11.01%) | 3,596 (63.24%) | 83,347 (9.64%) |
| Missing | 168,582 (72.77%) | 23,293 (66.73%) | 21,841 (3.71%) | 596,701 (68.99%) |
| Other | 2,432 (1.05%) | 1,045 (2.99%) | 1,282 (7.92%) | 24,185 (2.80%) |
| Prior COVID-19 positive | 4,747 (2.05%) | 2,097 (6.01%) | 1,512 (4.38%) | 64,511 (7.46%) |
| First vaccination visit type | ||||
| Outpatient visit | 17,373 (49.77%) | 15,431 (44.68%) | 345,383 (39.93%) | |
| Emergency visit | 131 (0.38%) | 97 (0.28%) | 1,729 (0.20%) | |
| Other | 153 (0.44%) | 265 (0.77%) | 6,406 (0.74%) | |
| Vaccination status | ||||
| Full initial vaccination | 28,537 (81.75%) | 31,530 (91.29%) | 765,929 (88.56%) | |
| Partial initial vaccination | 6,370 (18.25%) | 3,008 (8.71%) | 98,963 (11.44%) | |
| Booster vaccination (with full initial vaccination) | 8,415 (24.11%) | 14,730 (42.6%) | 460,967 (53.30%) | |
| Outcomes | ||||
| COVID-19 infection with hospitalization | 3,868 (1.67%) | 352 (1.01%) | 185 (0.54%) | 3,717 (0.43%) |
| Breakthrough/incident COVID-19 infection | 39,313 (16.97%) | 4,323 (12.40%) | 4,577 (13.30%) | 159,106 (18.40%) |
| Ventilation and/or ECMO | 162 (0.07%) | <20 | <20 | 118 (0.01%) |
| ICU | 52 (0.02%) | <20 | <20 | 84 (0.01%) |
Abbreviations: N3C=National COVID Cohort Collaborative; IQR= inter quantile range; CCI= Charlson Ccomorbidity Iindex; ER= emergency department; ECMO= extracorporeal membrane oxygenation; ICU= intensive care unit; COPD= Chronic obstructive pulmonary disease.
Prior COVID-19 positive was defined as whether they have prior COVID-19 diagnosis before the first vaccination date in Cohort 1 or before December.10, 2020 for unvaccinated pregnant people in Cohort 2.
COVID-19 severity outcomes include any hospitalization, including for a delivery, within 14 days before or 45 days after COVID-19 diagnosis; COVID-19-related hospitalization within 14 days before or 45 days after COVID-19 diagnosis but not within +/− 7 days of delivery date; ICU admission within 45 days after COVID-19 diagnosis; invasive ventilation or ECMO within 45 days after COVID-19 diagnosis.
Numbers in a category with number < 20 must be obfuscated to comply with the small number reporting rule for N3C.